<DOC>
	<DOCNO>NCT01432886</DOCNO>
	<brief_summary>The purpose study evaluate dose limit toxicity ( DLT ) , investigate tolerability safety eribulin mesylate trastuzumab combination therapy , estimate recommend dose .</brief_summary>
	<brief_title>A Study Eribulin Mesylate With Trastuzumab Advanced Recurrent Human Epidermal Growth Factor Receptor 2-Positive ( HER2+ ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion Criteria Females age great equal 20 year less 75 year time inform consent . Histologically cytologically confirm breast cancer Score 3+ immunohistochemistry ( IHC ) HER2 positive Fluorescence Situ Hybridization ( FISH ) method Subjects meet follow criterion : Evidence recurrence adjuvant chemotherapy trastuzumab taxane Evidence recurrence within 6 month adjuvant chemotherapy trastuzumab taxane Experienced prior chemotherapy include trastuzumab taxane advance recurrent breast cancer Adequate organ function Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Subjects submit write inform consent study entry Exclusion Criteria Subjects know brain metastasis accompany clinical symptom require active treatment Subjects severe active infection require active treatment Subjects large pleural effusion , ascites , pericardial effusion require drainage . Hypersensitivity trastuzumab , halicondrin B halicondrin B chemical derivative Known positive human immunodeficiency virus ( HIV ) test positive hepatitis B surface ( HBs antigen ) hepatitis C ( HCV ) serum test . Subjects pregnant ( positive BhCG test ) breastfeeding Subjects judge ineligible study principal investigator subinvestigator .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>